Regeneron’s anti-cholesterol drug Praluent reduces death risk in trial

This article was originally published here

Praluent (alirocumab), an anti-cholesterol drug being developed by Regeneron Pharmaceuticals and Sanofi, has succeeded in the Odyssey Outcomes trial by decreasing the risk of death and heart attack in high-risk patients.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply